摘要
Ⅱ期结肠癌术后是否需行辅助化疗，目前尚存争议。有研究表明，高危Ⅱ期结肠癌能从术后辅助化疗中获益。在临床病理特征方面，T4期、有穿孔和肿瘤周围淋巴管或血管浸润等的Ⅱ期结肠癌患者能从含有奥沙利铂的辅助化疗中获益；在基因分子水平方面，Ⅱ期结肠癌高微卫星不稳定性（MSI-H）表达较多，且不能从氟尿嘧啶化疗中获益，而染色体18q杂合子丢失（18qLOH）、Cx43及基因表达谱等在辅助化疗中的指导作用尚无定论，需进一步研究。
For stage Ⅱ colon cancer patients after surgery, the benefit of adjuvant chemotherapy remains controversial. Several studies indicate that the patients with high-risk stage Ⅱ colon cancer can benefit from adjuvant chemotherapy after surgery. According to the clinical and pathological features, the stage Ⅱ colon cancer patients including T4 lesion, perforation, peritumoral lymphovascular invasion can benefit from the adjuvant chemotherapy of oxaliplatin. In the horizontal of molecular and genetic levels, the stage Ⅱ colon cancer patients can express high microsatellite instability （MSI-H） and cannot benefit from the chemotherapy of Fluorouracil. The guiding functions of 18q loss of heterozygosity （ 18q LOH）, Cx43 and gene expression profi- ling in adjuvant chemotherapy are still unclear, and need further study.
出处
《国际肿瘤学杂志》
CAS
2013年第6期463-465,共3页
Journal of International Oncology
关键词
结肠肿瘤
微卫星不稳定性
杂合子丢失
Colonic neoplasms
Microsatellite instability
Loss of heterozygosity
